News

September 23, 2020 / A new article was published in Pharmaceuticals journal

Goltsov A, Swat M, Peskov K, Kosinsky Y. Cycle Network Model of Prostaglandin H Synthase-1. Pharmaceuticals 2020, 13, 265. 23 September. doi.org/10.3390/ph13100265
The network model of Prostaglandin H Synthase-1 (PGHS-1, COX-1) was developed, calibrated, and validated for its application to investigate its complex kinetics and in silico screening of NSAID efficacy in different in vitro and in vivo conditions.

September 16, 2020 / M&S Decisions took part in the MedicalAI round table

Kirill Zhudenkov on behalf of M&S Decisions team took part in the round table dedicated to the application of Artificial Intelligence and Machine learning techniques in international and Russian healthcare. The discussion involved the experts from biotech, healthcare providers, academia, as well as representatives from Novartis, Roche and Sanofi pharmaceutical companies.

September 02, 2020 / A new article was published in Frontiers in Oncology journal

V. Voronova, S. Lebedeva, M. Sekacheva, G. Helmlinger and K. Peskov. Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis. Front. Oncol., 02 September 2020 | https://doi.org/10.3389/fonc.2020.01609
Study results indicate significant improvement in overall survival of patients treated with combined radio- and immuno-therapy as compared to radiotherapy alone with a superiority of concurrent vs sequential administration of the two treatment modalities. No difference in radionecrosis rates between the groups received radiotherapy and combined radio- and immunotherapy was found.

May 29-31, 2020 / M&S Decisions attended the ASCO 2020 Virtual Scientific Program, USA

Researchers from M&S Decisions presented their work entitled “Comparative quantitative safety profiles of PD-1 and PD-L1 checkpoint inhibitor monotherapies: A Bayesian model-based meta-analysis” (Abstract # e15167). Comparison of safety profiles of PD-1 and PD-L1 checkpoint inhibitor monotherapies was shown using a Bayesian model-based meta-analysis.

May 22, 2020 / A new article was published in Frontiers in Oncology journal

V.Voronova, P. Glybochko, A. Svistunov, V. Fomin, P. Kopylov, P. Tzarkov, A. Egorov, E. Gitel, A. Ragimov, A. Boroda, E. Poddubskaya and M. Sekacheva. Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma. Front. Oncol., 22 May 2020, volume 10|https://doi.org/10.3389/fonc.2020.00832
Collaboration with Sechenov University is aimed to develop a multimarker diagnostic system to improve colorectal cancer detection. The system exploits several machine learning algorithms to calculate the risk of having the disease based on plasma levels of cancer-associated biomarkers.

May 21, 2020 / A new article was published in Oncoimmunology journal

Shulgin, B., Kosinsky, Y., Omelchenko, A., Chu, L., Mugundu, G., Aksenov, S., Pimentel, R., DeYulia, G., Kim, G., Peskov, K., & Helmlinger, G. (2020). Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology, 9(1), 1748982. https://doi.org/10.1080/2162402X.2020.1748982
Study results showed that unlike with PD-1 inhibitor monotherapy, CTLA-4 inhibitor monotherapy exhibited  a dose/exposure dependence on most AE types evaluated. Furthermore, combination therapy with PD-1 inhibitor significantly strengthened the dependence of trAE and imAE rates on CTLA-4 inhibitor dose/exposure.

February 26, 2020 / A new article was published in Cellular and Molecular Gastroenterology and Hepatology journal

Voronova V., Sokolov V., Al-Khaifi A., Straniero S., Kumar C., Peskov K., Helmlinger G., Rudling M., Angelin B. A physiology-based model of bile acid distribution and metabolism under healthy and pathological conditions in humans. Cell Mol Gastroenterol Hepatol. 2020 Feb 26.
This collaborative work with Karolinska University group is aimed to evaluate the impact of gastrointestinal perturbations on the levels of three key bile acids within enterohepatic and systemic circulation.

February 16, 2020 / A new article was published in CPT: Pharmacometrics & Systems Pharmacology

Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Feb 16. doi: 10.1002/psp4.12498
This manuscript describes an application of the previously published QSP model (Yakovleva T et al., Diabetes Obes Metab (2019) 21, 2684-2693) to the differentiation of the clinical effects observed for the gliflozins, currently available on the market based on their capacity to inhibit sodium-glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes

February 6-8, 2020 / M&S Decisions attended the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium, Orlando, FL, USA

Kirill Peskov presented the work “Quantification of dose dependence and frequency of checkpoint inhibitor immune-mediated adverse events: A Bayesian model-based meta-analysis” (Abstract №83) at the poster session. A novel meta-analysis methodology was introduced and used to quantify and compare adverse events rates across immune checkpoint inhibitors agents.

22 January / 23 January 2020, M&S Decisions attended the Japan Pharmacometrics Conference 2020 (JPC2020) held in Tokyo, Japan.

Victor Sokolov made a presentation entitled “Dapagliflozin Exposure–Response in Japanese vs Non-Japanese Patients with Type 1 Diabetes” based on exposure-response analysis included in the registration dossier supporting dapagliflozin submission in PMDA.

20 January 2020, M&S Decisions presented at the IT lecture series, held in HSE, Moscow, Russia.

02 December / 05 December 2019, M&S Decisions held the School of Mathematical Modeling in drug design in Moscow, Russia.

On 2 – 5 December 2019 M&S Decisions scientists gave lectures at our annual School of Mathematical Modeling, the fourth year in a row. The School Program contained an open lecture day, followed by two days of practice based on industry cases and a training day in effective scientific communications. Participation is free of charge, but applicants had to go through the competition. In 2019, the competition amounted to 7 people per place. Traditionally participants received certificates on completion.

23 November 2019, M&S Decisions presented at the “FIT-M: Industry/Business/Science” conference held in Moscow, Russia.

Victor Sokolov gave a lecture on the application of mathematical modeling in the research and development process of new medicines.

20 October / 23 October 2019, M&S Decisions attended the Tenth American Conference on Pharmacometrics (ACoP10) held in Orlando, FL, USA.

Victor Sokolov and Kirill Peskov presented a research study (poster T-79) built upon previously presented at ACoP9 work on utility analysis of five different packages available for MATLAB and R by evaluating functionalities of the MATLAB SimBiology toolbox within a QSP modeling workflow framework.

25 September / 28 September 2019, M&S Decisions participated in the FIFTH INTERNATIONAL IMMUNOTHERAPY CONFERENCE – CICON 2019, Paris, France

Collaborative work with experimenters from AstraZeneca pharmaceutical company entitled «Using Quantitative Systems Pharmacology modeling to predict response and resistance of immune checkpoint inhibitors (ICI) in murine syngeneic tumors» (Poster B154) was presented by Kirill Peskov and Ivan Azarov. The main message of this work was that the mechanistic quantitative immuno-oncology model demonstrated its suitability for predicting tumor size dynamics in response to various immune inhibitors for several syngeneic tumors.

27 September / 01 October 2019, M&S Decisions will participate in the annual congress of European Society of Medical Oncology (ESMO), Barcelona, Spain

A collaborative work with Sechenov University entitled “Evaluation and diagnostic potential of plasma biomarkers in bladder cancer” (Poster №1868) will be presented by Veronika Voronova. The research focuses on the application of machine learning tools to develop a multi-protein biomarker for cancer screening.

September 17, 2019 / A new article was published in The Journal of Lipid Research

Victor Sokolov, Gabriel Helmlinger, Catarina Nilsson, Kirill Zhudenkov, Stanko Skrtic, Bengt Hamrén, Kirill Peskov, Eva Hurt-Camejo, and Rasmus Jansson-Löfmark. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. J Lipid Res. 2019 Sep; 60(9): 1610–1621. doi: 10.1194/jlr.M092486

Our team in collaboration with AstraZeneca developed an integrative systems pharmacology model of lipoprotein homeostasis which sets the stage for the quantitative benchmarking of two anti-PCSK9 pharmacological modality classes, monoclonal antibodies, and small interfering RNA, by describing in minimalistic yet mechanistic terms complex interactions between multiple plasma lipoprotein and lipid biomarkers, and by establishing a quantitative link between plasma PCSK9 and low-density lipoprotein cholesterol reduction for five different anti-PCSK9 compounds.

August 24, 2019 / M&S Decisions participated in International Summer Biological School Pilgrim

Varvara Ustinova gave a lecture on mathematical modeling in drug development for high school students at the International Summer Biological School Pilgrim.

The participants learned about the process of drug development and the role of mathematical modeling in research and development of new medicines, as well as basic principles of pharmacometrics and model development workflow.

August 18, 2019 / A new article was published in Diabetes, Obesity and Metabolism

Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J. Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes Metab. 2019 Aug 18. doi: 10.1111/dom.13858.

 Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of oral glucose-lowering compounds used to treat type 2 diabetes mellitus (T2DM). In collaboration with AstraZeneca quantitative drug-disease systems model was developed and used to reveal mechanistic differences in renal glucose reabsorption and urinary glucose excretion (UGE) between healthy and T2DM patients and clearly showed that SGLT2 inhibition significantly increased glucose available to SGLT1 downstream in the tubule. 

August 20-23, 2019 / M&S Decisions participated in StanCon 2019 Conference, Cambridge, UK

Researchers from M&S Decisions LLC shared their experience in joint modeling of longitudinal biomarker and time-to-event data for mCRPC as well as presented the work on Bayesian meta-analysis for IO therapy safety at StanCon 2019 Conference, a conference devoted to the application of Bayesian methods in the data science and pharmacology.

June 11-14, 2019 / M&S Decisions participated at PAGE 2019 Conference, Stockholm, Sweden

M&S Decisions shared its experience in joint modeling of multivariate longitudinal biomarker and time-to-event data for COPD and NSCLC by presenting two scientific works at PAGE 2019 Conference.

June, 2019 / A new article was published in Frontiers in Immunology

Azarov, I., Peskov, K., Helmlinger, G., & Kosinsky, Y. (2019). Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study. Frontiers in Immunology, 10, 1289. doi: 10.3389/fimmu.2019.01289

The collaborative work of the authors from M&S Decisions and AstraZeneca is devoted to the mechanistic description of the naive T cells activation inside the lymph node’s T-zone and the immune response initiation. The study was carried out using agent-based modeling.
Current research has convincingly shown that the predominant type of motion of naive lymphocytes is random motion. On the other hand, selective chemotaxis motion of activated cognate T cells in the direction of dendritic cells is critical for reproducing the cognate clones expansion and the immune response development.

May 13-17, 2019 / M&S Decisions participated in the Pharma’s cool organized by Skolkovo Biomedical Cluster and Skolkovo Open University

Kirill Peskov and Tatiana Yakovleva participated in the Pharma’s cool and Job Fair held at Skolkovo Biomedical Cluster in May 13-17, 2019.

Kirill and Tatiana gave a talk about application of mathematical modeling in Pharma R&D and biomedical research.

If you are interested in Pharma R&D work and was unable to attend M&S Decisions on May 17, 2019 at Job Fair in Skolkovo please be welcome on our Careers page.

April, 2019 / A modeling work by David Busse was accepted for publication in British Journal of Clinical Pharmacology

In April, 2019 a modeling work by David Busse et al. investigating pharmacokinetics and the exposure-response relationship of dapagliflozin in adolescent and adult patients with type 1 diabetes mellitus was accepted for publication in British Journal of Clinical Pharmacology.

April, 2019 / A new article was published in Frontiers in Immunology

Kirill Peskov, Ivan Azarov, Lulu Chu, Veronika Voronova, Yury Kosinsky, Gabriel Helmlinger. Quantitative mechanistic modelling in support of pharmacological therapeutics development in immuno-oncology. Front. Immunol. doi: 10.3389/fimmu.2019.00924

This mini-review focuses on the evolution and state-of-the-art of quantitative systems models describing the tumor vs. immune system interplay, and their merging with quantitative pharmacology models of IO-modulating agents, as companion tools to support the addressing of the IO drug development challenges.

April 12, 2019 / M&S Decisions participated in the Digital Medicine Forum organized by the I. M. Sechenov First Moscow State Medical University

M&S Decisions took part in the Medicines Digital Forum. Kirill Peskov, CEO of M&S Decisions LLC, gave a talk at the section Innovations of the Pharmaceutical Marker: “Breakthrough Technologies & Innovations – Smart Drugs”.

April, 2019 / A new research article about urinary glucose excretion under SGLT2 inhibitor treatment was published in Diabetes, Obesity and Metabolism

In April, 2019 a new research article comparing urinary glucose excretion under SGLT2 inhibitor treatment between Japanese and non-Japanese patients with type 1 diabetes mellitus was published in Diabetes, Obesity and Metabolism.

Sokolov V, Yakovleva T, Ueda S, Parkinson J, Boulton D W, Penland R C, Tang W. Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes Obes Metab. 2019; 21:829–836

March 29 – April 3, 2019 / M&S Decisions took part in the Annual Meeting of American Association of Cancer Research 2019

M&S Decisions took part in the Annual Meeting of American Association of Cancer Research 2019 in Atlanta, US, where two works were presented:

  • “Mechanistic insights and dose optimization for AZD3458, a novel selective PI3Kʏ immuno-modulator, using a quantitative systems approach”;
  • “Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach”.

December 3-6, 2018 / Mathematical modeling in drug development school in Skolkovo

modeling_school

In December, 2018 Skolkovo Biomedical cluster, Open Skolkovo University and M&S Decisions LLC in partnership with the AstraZeneca company organized a 4-day workshop about mathematical modeling in drug development.

The goal of the workshop was to introduce participants to the basics of pharmacometrics and systems pharmacology and show how these modeling techniques can help to solve R&D questions and support decision making at different stages of drug development pipeline.

Mathematical modeling school in pharmaceuticals has become traditional for Skolkovo and was held for the third time.

November 7-11, 2018 / M&S Decisions team presented results of collaboration with AstraZeneca on the Immune Oncology modeling platform development at the Annual Meeting of The Society for Immunotherapy of Cancer (SITC)

The 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) was held on the 7-11th of November at the Walter E. Washington Convention Center  in Washington, D.C. where M&S Decisions team presented results of collaboration with AstraZeneca on the Immune Oncology modeling platform development.

October 26, 2018 / M&S Decisions took part in the session of BiotechClub 2018: From Systems Biology to Systems Medicine

Kirill Peskov, CEO of M&S Decisions LLC, give a talk at the section Bioinformatics: “Constructive biotechnologies: the power of mathematical modelling”.

October 7-10, 2018 / M&S team participated in the 9th American Conference on Pharmacometrics organized by the annual scientific meeting of the International Society of Pharmacometrics, USA

Kirill Peskov, Yuri Kosinsky, Kirill Zhudenkov, Veronika Voronova and Victor Sokolov went to sunny San-Diego to prove that «Modeling without Bounds» are not just words: keep up with our latest modeling updates in oncology, metabolic diseases and industrialization.

October 3, 2018 / Job Fair, Skolkovo Biomedical cluster

M&S Decisions participated in the 5th annual event aimed at recruiting young biomedical technology specialists for open positions and internship at companies participating in the Biomedical Cluster and Skolkovo Foundation.

Our company has an open position of Visiting scientist, mathematical modelling. The details are available at M&S Decisions website – Career page.

A collaborative work with Karolinska university group entitled “A physiology-based model of the distribution of individual bile acids within the enterohepatic circulation under normal and pathological conditions in human” was presented by Veronika Voronova.

July 02, 2018 / A new study on enterohepatic circulation of bile acids was published in Journal of Internal Medicine

Researchers from M&S Decisions in collaborative work with Karolinska utilized advanced data analysis techniques to investigate kinetics of bile acid-mediated Farnesoid X receptor activation.

May 27 – June 1, 2018 / M&S Decisions participated in IQR workshop and made two scientific presentations at PAGE 2018 Conference, Montreux, Switzerland

Researchers from M&S Decisions LLC shared their experience in mathematical modeling of bile acids enterohepatic circulation and industrialization of systems pharmacology model development by presenting two scientific works at PAGE 2018 Conference in Montreux, Switzerland, after participating in a full-day modeling workshop organized by IntiQuan company:

  • A functional, integrative R environment workflow for the development and use of quantitative systems pharmacology models presented by Artem Dolgun
  • Using a physiologically-based QSP model to simulate the effects of enterohepatic circulation perturbations on the distribution of bile acids presented by Veronika Voronova

May 14-18, 2018 / A new article about QSP modeling was published in Diabetes, Obesity and Metabolism

A QSP model was used to show that gastric emptying inhibition by exenatide represents an important additional mechanism of postprandial glucose stabilization. The drug effect depends on the food properties, which underscores the importance of dietary counseling as an adjunct to medication.

Voronova V, Zhudenkov K, Penland RC, Boulton DW, Helmlinger G, Peskov K. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model. Diabetes Obes Metab. 2018; 1–5. 

May 14-18, 2018 / M&S Decisions participated in the V Congress of pharmacologists of Russia “Scientific basis of search and development of new drugs”, held in Yaroslavl

Researchers from M&S Decisions made a presentation, summarizing usage of multiple quantitative clinical pharmacology methodologies on different stages of drug development.

April 14-18, 2018 /  M&S Decisions took part in the Annual Meeting of American Association of Cancer Research 2018

M&S Decisions took part in the Annual Meeting of American Association of Cancer Research 2018 where we presented the work “Quantitative modeling as a systematic approach for drug combination evaluation in Immuno-Oncology”.

A mechanistic model describing interactions among host immune cells and tumor cells was developed. The proposed model was used to explore the effects of PD-1 and CTLA-4 immune checkpoint inhibitors, OX40 agonistic ligand and CXCR2 blocking antibody, and their combinations, on tumor microenvironment and tumor growth dynamics in various experimental murine models. The types of synergistic effects which may arise from immuno-oncology drug combinations were categorized across realistic baseline conditions prevailing in the tumor microenvironment (TME).

March 21-24, 2018 / M&S Decisions made two scientific presentations  in collaboration with AstraZeneca at ASCPT 2018 Annual Meeting, Orlando, FL, USA

At ASCPT 2018 Annual Meeting, one of the biggest clinical pharmacology conferences in the US, M&S Decisions LLC presented two systems pharmacology models developed in collaboration with AstraZeneca:

  • Differentiation of anti-PCSK9 antibodies and synthesis inhibitors: a drug-disease modeling study presented by Victor Sokolov;
  • Contribution and regulation of SGLT1 and SGLT2 in healthy and type 2 diabetes subjects: a drug-disease modeling study presented by Tatiana Yakovleva.

Also during the session on Immuno-Oncology therapeutic combinations Gabriel Helmlinger in the talk “Quantitative Systems Pharmacology Modeling to Inform Combination Strategies in Immuno-Oncology” presented the key results of collaboration between AstraZeneca company and M&S Decisions LLC.

March 20, 2018 / M&S Decisions took part in the meet-up “Predicting  drug efficacy and clinical outcomes using different quantitative methods” held in Volgograd State Medical University

Researchers from M&S Decisions shared their experience in usage of QSP, PBPK, pop-PK/PD modeling in optimization of clinical trial design.

February 27, 2018 / New article on immuno-oncology QSP modeling was published in the Journal of ImmunoTherapy of Cancer

New article on immuno-oncology QSP modeling was just published in the Journal of ImmunoTherapy of Cancer.

A mathematical model is presented. It integrates key mechanistic features of immuno-oncology biology, radiation and anti PD-L1 pharmacokinetics, to accurately predict optimal radiation and anti PD-L1 dose sequencing for maximal anti-tumor efficacy. Owing to its mechanistic nature, the model features mechanistic insights into the immune-suppressive vs. immuno-activating forces underlying drug regimen optimization.

Yu. Kosinsky, S. Dovedi, K. Peskov, V. Voronova, L. Chu, H. Tomkinson, N. Al-Huniti, D. Stanski, G. Helmlinger. (2018) Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model, Journal for ImmunoTherapy of Cancer (2018) 6:17

January 25, 2018 / Future Biotech Winter Retreat 2018

Yuri Kosinsky and Oleg Stepanov, researchers from M&S Decisions, gave practical training “Introduction to pharmacometrics and population analysis” for young scientists at Future Biotech Winter Retreat 2018.

December 15, 2017 / Big Data in Pharma conference by Semantic Hub

The Big Data in Pharma conference overviewed the big data spectrum in pharmaceutical development and the ways of its utilization.

M&S Decisions took part in this conference and Kirill Zhudenkov gave a report on the decision making in drug development.

December 4-7, 2017 / Mathematical modeling at drug development school in Skolkovo

modeling_school

M&S Decisions, Skolkovo Biomedical cluster and Open Skolkovo University held a 4-day conference and workshop, devoted to the mathematical modeling in drug development. The event was targeted to PhD students, postdocs and young scientists.

The wide range of topics was presented and studied: the principles of model-based drug development, the basics of PBPK, quantitative systems pharmacology, pharmacometrics etc. The attendees of the conference collected unique experience of working in modern R&D projects for  innovative drugs.

November 14-16, 2017 / XXI Russian Congress on Oncology

During the XXI Russian Congress on Oncology a special session was devoted to the presentation of Skolkovo startups performing the research in oncology. Yuri Kosinsky from M&S Decisions gave a presentation on the research of IO+RT in terms of immune response and dose regimen optimization.

November 1-3, 2017 / Pharmacokinetics PKUK 2017 Meeting

Pharmacokinetics UK (PKUK) was a spin out from the DMDG (Drug Metabolism Discussion Group) in early 80s. Since those times the conference is held on the regular basis in the UK.

M&S Decisions attended the PKUK Meeting 2017, where Yuri Kosinsky made a report on radiation and anti-PD-L1 treatment combinations.

October 16-18, 2017 / Open Innovations forum in Skolkovo

The annual Open Innovations forum has been held in Moscow since 2012 under the aegis of the Government of the Russian Federation and is considered as a unique discussion platform for participants in the formation of an innovative ecosystem.

M&S Decisions attended the Open Innovations forum in Skolkovo. Kirill Peskov took part in the discussion session “To keep pace with technologies. How to regulate new medicine?”

October 14-19, 2017 / American Conference on Pharmacometrics (ACoP)

M&S Decisions attended the ACoP 2017 conference where a set of works devoted to the investigation of modeling methodology and disease areas: metabolic, respiratory and oncology, was presented.

September 25-26, 2017 / AZ-Medimmune Cancer Symposium

M&S Decisions attended the 3rd AstraZeneca-MedImmune-CRUK Cancer Symposium, Cambridge, the UK.

Kirill Peskov, CEO of M&S Decisions LLC, presented the work “Radiation and anti-PD-(L)1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach” made by M&S Decisions in collaboration with AstraZeneca and MedImmune.

September 22, 2017 / Job Fair, Skolkovo Biomedical cluster

This project is aimed at recruiting young biomedical technology staff for employment and traineeships at companies participating in the Biomedical Technologies Cluster, pharmaceutical manufacturers, and the Skolkovo Foundation.

M&S Decisions took part in this event, established new communications and selected several candidates for a new position in the company.

Our company has open positions. The details are available at HH, Molbiol, LinkedIn or M&S Decisions website – Career page.

June 9-13, 2017 / M&S Decisions made scientific presentations at American Diabetic Association (ADA) conference, San Diego, California

Victor Sokolov, a researcher from M&S Decisions LLC, presented the work “Comparison of Lipid-Lowering Properties of Anti-PCSK9 Antibodies and Synthesis Inhibitors Using a Quantitative Systems Model of Lipoprotein Metabolism”  made by M&S Decisions in collaboration with AstraZeneca at Scientific Sessions of American Diabetic Association (ADA), San Diego, USA

June 6-9, 2017 / M&S Decisions made four scientific presentations at PAGE 2017 Conference, Budapest, Hungary

March 15-18, 2017 / M&S Decisions made scientific presentation in collaboration with AstraZeneca at ASCPT Annual Conference at Washington DC, USA

Dmitry Onishchenko, a scientist from M&S Decisions LLC presented at Washington DC the work made in collaboration with AstraZeneca – “Dynamic prediction of progression free survival (PFS) and overal survival (OS) in Non-small cell lung cancer (NSCLC) using tumor size: A longitudinal joint modeling approach” at the Annual Conference of ASCPT (American Society for Clinical Pharmacology and Therapeutics), the USA, 2017. The presented poster was selected as the Top Posters category.

March 3-7, 2017 / M&S Decisions made scientific presentations at Keystone symposia: Bile Acid Receptors as Signal Integrators in Liver and Metabolism, Monterey, USA

Veronika Voronova, a researcher from M&S Decisions LLC, presented the work “Systems Pharmacology Modeling of Bile Acid Distribution and Signaling”  made by M&S Decisions in collaboration with AstraZeneca and Karolinska institute, Sweden at Keystone conference: Bile Acid Receptors as Signal Integrators in Liver and Metabolism in Monterey, the USA.

February 23-25, 2017 / M&S Decisions made scientific presentation in collaboration with AstraZeneca at ASCO-SITC Immuno-Oncology Symposium in Orlando, USA

M&S Decisions LLC presented the work made in collaboration with AstraZeneca “Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy” at ASCO-SITC Immuno-Oncology Symposium in Orlando, the USA.

M&S Decisions together with Skolkovo Biomedical Technologies Cluster and Skolkovo Open University organized a school on Mathematical modelling in pharmaceutics for biomedical startups and young scientists in Skolkovo Foundation.

The aim of the school was to introduce to the participants the core methods of mathematical modelling, which were widely used for decisions making process during new drugs development.

More than 200 young specialists took part in the event, including undergraduate and post-graduate students from leading Russian universities such as Moscow State University, Moscow Institute of Physics and Technology, Mendeleev University of Chemical Technology, Sechenov First Moscow State Medical University, National Research Medical University, Mechnikov North-Western University, Altai State University and others.

On the first day of the school the Skolkovo Hypercube brought together specialists from different areas of biology, chemistry and medicine where mathematical model was actively used. Young scientist had lectures on methods how mathematical modelling was used on different stages of drugs development including:

  • different phases of clinical and preclinical trials
  • making decisions at drug development
  • special focus was made on immuno-oncological research

The second and the third days of the school were devoted to lections and practical trainings in Pharmacometrics, Systems Pharmacology and Translation modelling.

M&S Decisions lead scientists Yuri Kosinsky and Kirill Peskov  at the U.S. FDA, Washington DC.

Kirill Peskov and Yuri Kosinsky, the lead scientists at M&S Decisions, participated in the scientific seminar at the FDA, a federal agency responsible for the regulation and supervision of pharmaceutical drugs in the U.S.A. The seminar was focused on innovative methods in mathematical modeling, to improve the therapeutic outcome of novel drugs in the treatment of cancer. A new quantitative methodological platform, developed in collaboration between Skolkovo resident M&S Decisions and the pharmaceutical company AstraZeneca, was presented. The platform included a combination of modeling approaches, including systems pharmacology, pharmacometrics, and meta-analyses. It was under further development and validation work to predictively assess the therapeutic potential of novel oncology drug combinations, including the prediction of key endpoints in drug development clinical trials.

This combination of modeling approaches resulted in the creation of a ‘modeling continuum’ along pharmaceutical R&D pipeline, thereby enabling constant support towards decision-making, from preclinical to first-in-human trials, and from early clinical trials to late-phase and registration trials. ‘How’ and ‘where’ in the pipeline such quantitative modeling may support transition points and decisions, and how it may help better identify patient subpopulations who respond to specific combination therapies, were debated in a lively and interactive Q&A session that followed the presentation, and during which the overall methodology platform was seen as “progressive.”

September 16-20, 2016 / M&S Decisions made three scientific presentations at ICSB 2016 Conference, Barcelona, Spain

Researchers from M&S Decisions LLC made three scientific publications at ICSB 2016 conference in Barcelona, Spain, which was the biggest European conference on Systems Biology.

M&S Decisions researchers gave the presentations and two posters:

  • Quantitative Systems Pharmacology model for immuno-oncology drug development: example of CTLA4 inhibition mechanism, presented by Yuri Kosinsky
  • Enhancement of cytokine signaling via cytokine-neutralizing antibodies, presented by Boris Shulgin
  • A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions, presented by Kirill Peskov

June 7-10, 2016 / M&S Decisions made six scientific presentations at PAGE 2016 Conference, Lisboa, Portugal

April 28, 2016 / Scientists Reveal the Secret of Antibiotic-resistant Bacteria

Researchers from Moscow Institute of Physics and Technology, M&S Decisions LLC and Yandex LLC built a computer agent based model of the interaction between different bacteria, and between bacteria and the gut wall. This led them to explain how antibiotic-resistant microbes develop and spread; details of the study were published in the journal PLOS ONE.

The human intestine contains trillions of different bacteria, which together are called the microbiome. Bacteria protect us from harmful microorganisms, produce digestive enzymes, and help the immune system to function normally. Many diseases, such as obesity, Crohn’s disease, colon cancer, and other inflammatory processes are associated with a change in the gut microbiome. The researchers built a model of the interaction between two types of bacteria and the intestine and they determined what happened when they took antibiotics that killed a large number of microorganisms.

Source: MIPT press release

April 4, 2016 / Lecture by Kirill Peskov at Skolkovo foundation “Pharma’s Cool” program

Kirill Peskov, Managing Director and Senior Principal Scientist of M&S Decisions LLC presented a lecture on the topic “Pharmacometrics and model based drug development” at Pharma Cool School organised by Skolkovo foundation.  Read more